Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

Authors: Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fields, Karin Havenith, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven M. Horwitz - The Lancet 2021 cited by 86